Nasdaq Pali News Today

Maxim Group reissued their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a report released on Wednesday, Benzinga reports. Maxim Group currently has a $22.50 price objective on the stock. Palisade Bio Price Performance NASDAQ:PALI opened at $7.08 on Wednesday. The company’s 50 day moving average is $5.70 and its 200-day […]

Maxim Group restated their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a research report report published on Tuesday, Benzinga reports. The firm currently has a $22.50 price target on the stock. Palisade Bio Price Performance Shares of Palisade Bio stock opened at $4.71 on Tuesday. Palisade Bio has a 1 […]

Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,000,000 shares, an increase of 1,450.4% from the January 15th total of 129,000 shares. Currently, 25.7% of the company’s stock are short sold. […]

Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology,...

Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company...

Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company...

– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity...

Palisade Bio (NASDAQ:PALI – Get Free Report) and DBV Technologies (NASDAQ:DBVT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends. Analyst Recommendations This is a summary of […]

Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 34,900 shares, a drop of 47.6% from the November 15th total of 66,600 shares. Based on an average daily volume of 176,500 shares, the days-to-cover ratio is presently 0.2 […]

Maxim Group upgraded shares of Palisade Bio (NASDAQ:PALI – Free Report) from a hold rating to a buy rating in a research report report published on Friday, Benzinga reports. Maxim Group currently has $1.50 price objective on the stock. Palisade Bio Trading Down 0.8 % Shares of Palisade Bio stock opened at $0.60 on Friday. […]